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  D
yslipidaemia, characterised 
by elevated total cholesterol, 
elevated non–high density 
lipoprotein (HDL) cholesterol, 
low HDL cholesterol, and elevated 
triglycerides, is common in patients 
with HIV who are treated with long-
term antiretroviral therapy (ART) 
[1]. Although multiple factors 
inﬂ  uence lipid levels in patients 
treated with ART, exposure to protease 
inhibitors (PI) is thought to play an 
important role in the development 
of dyslipidaemia [2,3]. Data showing 
a relationship between length of 
exposure to ART and increased 
incidence of cardiovascular events [4] 
have heightened concern that ART-
associated dyslipidaemia will result 
in increased rates of cardiovascular 
disease among ART-treated patients 
with HIV.
    The pathogenesis underlying 
ART-associated dyslipidaemia is 
thought to be related to drug-
induced effects at the subcellular 
or molecular level [5–7]. This 
pathogenic mechanism, together 
with the interindividual variability in 
the prevalence and severity of ART-
associated dyslipidaemia, suggests an 
important role for genetic factors in 
the pathogenesis of this dyslipidaemia. 
Small variations in genetic sequence, 
or single-nucleotide polymorphisms 
(SNPs), are common in the human 
genome [8]; many adverse drug 
reactions occur in response to drugs 
that are metabolised by enzymes 
known to contain functionally relevant 
polymorphisms [9]. Determining 
the effect of SNPs or groups of 
SNPs (halotypes) on an individual’s 
response to either drugs or disease 
may help to limit these adverse drug 
reactions. This area has become a 
focal point of translational molecular 
research.
  Triglycerides  and  ApoC-III
    Apolipoproteins (apo) are important 
components of circulating lipoproteins. 
ApoC-III, a 79–amino acid glycoprotein 
synthesised in the liver and small 
intestine, is a major constituent of 
chylomicrons and very low density 
lipoproteins (VLDLs), both of which 
are triglyceride-rich lipoproteins. 
ApoC-III regulates the synthesis and 
catabolism of VLDL, an important 
contributor to plasma triglyceride 
concentrations [10]. In human studies, 
levels of apoC-III showed a positive 
correlation with plasma triglycerides, 
and higher apoC-III concentrations 
have been associated with recurrent 
cardiovascular events [11]. In studies 
of people with HIV, apoC-III levels 
showed a positive correlation with 
triglyceride concentrations in males 
with HIV [12], and apoC-III levels in 
males treated with PI were two to three 
times higher than controls [13].
  Inﬂ  uence of Polymorphisms 
on ApoC-III Function
    Regulation of apoC-III occurs at 
the level of its transcription. Insulin 
interacts with an insulin-responsive 
element in the promoter region 
of apoC-III, resulting in down 
regulation of apoC-III expression 
[10]. Within the insulin-responsive 
element, the presence of two apoC-
III polymorphisms, −455T/C and 
−482C/T, affects the ability of insulin 
to down-regulate apoC-III expression 
in vitro [14]. These polymorphisms 
are common in populations infected 
with HIV [15,16]. Along with another 
polymorphism in the 3′ untranslated 
region termed SstI (3238C/G), these 
polymorphisms have been associated 
with hypertriglyceridaemia in studies 
of both HIV-positive and -negative 
populations [10,14–17].
    Two previous studies in patients with 
HIV explored the relevance of apoC-
III polymorphisms to ART-associated 
dyslipidaemia. In one study, 60% 
of individuals expressing all three 
apoC-III variants together with an 
apoE variant experienced extreme 
hypertriglyceridaemia (greater than 7 
mmol/l) when exposed to ritonavir, 
values more than two times those of 
patients with similar genetic proﬁ  les 
not on ART treatment [16]. In another 
study, patients receiving PI who carried 
the −482T or −455C alleles had higher 
triglycerides (50%–60% higher) than 
patients with wild-type apoC-III [15].
    Both studies had limitations. In the 
smaller study, the 60 patients were all 
White men prescribed PI-containing 
ART [15], and patients with pre-
therapy dyslipidaemia were excluded. 
Only 21% of the data points studied 
were in patients taking ritonavir, a PI 
associated with dyslipidaemia [3] that 
is now increasingly used in small doses 
to pharmacologically “boost” the levels 
of other PIs. Although the larger study 
(  n   = 329) included women (21%), 
the cohorts were still predominantly 
White (88%) [16]. As there are 
large racial/ethnic differences in 
the prevalence of not only HIV [18] 
but also metabolic syndrome and 
dyslipidaemia [19], it is also important 
to determine the different effects of 
potentially functional polymorphisms 
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across racial/ethnic groups if 
pharmacogenetic and genomic 
knowledge is to be applied to the 
treatment of diverse populations. These 
studies were not designed to address 
these issues.
    A New Study in a Racially/
Ethnically Diverse Population
    In the current issue of   PLoS Medicine  , 
Foulkes et al. describe associations 
between apoC-III polymorphisms and 
triglyceride concentrations in a large 
(  n   = 626) population of patients with 
HIV from a variety of racial/ethnic 
backgrounds [20]. A strength of this 
study was that it derived samples and 
collected data through the Adult AIDS 
Clinical Trial Group (AACTG) A5128 
Protocol, which allows for storage 
of DNA for pharmacogenetic and 
genomic research from participants 
enrolled in a range of AACTG clinical 
trials [21]. In contrast to other studies, 
19.3% of the population was Black/
non-Hispanic and 17.9% was Hispanic, 
allowing for investigations into the 
effect of the apoC-III polymorphisms 
both within and between different 
racial/ethnic populations.
    Foulkes et al. found wide variability 
in genotype frequency among different 
racial/ethnic groups with wild type less 
common among Black/non-Hispanics 
(10.8%) than among White/non-
Hispanics (45.5%) and Hispanics 
(35.1%). The pattern and severity of 
dyslipidaemia also differed between 
groups. Although the Black/non-
Hispanic group had lower triglycerides, 
lower non-HDL cholesterol, and 
higher HDL cholesterol levels than 
White/non-Hispanics and Hispanics, 
they experienced more pronounced 
increases in triglycerides in response to 
PI-containing ART.
    In contrast to previous literature, 
presence of variant apoC-III alleles 
in the Hispanic group was associated 
with a seemingly protective effect 
when exposed to PIs, as patients 
carrying these variant alleles had 
lower triglyceride values in response 
to PIs than those carrying wild type. 
Although seemingly counterintuitive, 
similar protective effects of variant 
allele combinations have been 
previously described in people who 
are HIV-negative [17], even though 
an underlying mechanism has yet 
to be determined. These data point 
to speciﬁ  c differences between 
racial/ethnic groups, not only in the 
prevalence of apoC-III polymorphisms, 
but also in the inﬂ  uence of these 
polymorphisms on PI-related 
hypertriglyceridaemia.
    This study does have some 
limitations. For example, women were 
underrepresented (11% compared to 
the 25% of North American people 
living with HIV who are women [18]); 
only 10% of patients on PI therapy 
were on ritonavir; and, as the authors 
acknowledge, the study still lacked 
the power to detect small interaction 
effects within different racial/ethnic 
groups. Nevertheless, this study 
demonstrates speciﬁ  c differences 
between racial/ethnic groups in both 
the occurrence of dyslipidaemia on 
ART and the inﬂ  uence of genetic 
factors on the prevalence of PI-related 
lipid abnormalities.
  Pharmacogenetics  and 
Antiretroviral Therapy
    The study by Foulkes et al. is among an 
increasing number of pharmacogenetic 
studies in HIV. Genetic variation has 
been linked to the metabolism of 
antiretroviral drugs [22–24], drug 
hypersensitivity [25], and components 
of HIV-associated lipodystrophy 
[26–29] (Table 1), although several 
of these studies were small, enrolled 
  Table 1.   Pharmacogenetic/Genomic Studies in HIV   
Study Gene(s) Polymorphism(s)/ 
Alleles
n Percent 
Male
Region Race/Ethnicity Summary of Findings
Fauvel et al. [15] APOC3 455T/C, 482C/T, SstI 60 100% Europe Not studied All three polymorphisms positively associated 
with triglyceride concentrations.
Tarr et al. [16] APOC3 APOE 455T/C, 482C/T, SstI; ε2, 
ε4 alleles
329 79.3% Europe 88% White, 7% Black, 
3% Hispanic
High triglycerides with ritonavir treatment in 
individuals with APOC3 and APOE variants.
Nolan et al. [28] TNFα 238G/A 191 100% Australasia 100% White Increased risk of progression to lipodystrophy 
in heterozygotes.
Maher et al. [29] TNFα 238G/A 96 89% Europe 100% White Higher frequency of 238G/A polymorphism in 
patients with lipodystrophy.
Tarr et al. [16] TNFα 238G/A 329 79.3% Europe 88% White, 7% Black, 
3% Hispanic
No effect of TNFα polymorphism on 
development of lipoatrophy.
Fellay et al. [23] MDR1 CYP2D6 3435C/T; *3, *4, *6 alleles 123 Not studied Europe 100% White Lower plasma antiretroviral concentrations 
with 3435C/T polymorphism. Higher plasma 
antiretroviral concentrations with variant 2D6 
allele.
Rotger et al. [24] CYP2B6 516G/T 226 Europe Greater NNRTI plasma concentrations in 
patients with 516T/T.
Haas et al. [22] CYP2B6 516G/T 154 82% North America 57% White, 32% 
Black, 10% Hispanic
Higher efavirenz levels and more early central 
nervous system side effects in individuals with 
516G/T polymorphism.
Yang et al. [27] SREBP1 322C/G 355 80% International 57% White, 25% 
Black, 13% Hispanic
Presence of polymorphism not predictive of 
hyperlipidaemia.
Miserez et al. [26] SREBP1 322C/G 71 Not studied Europe Not studied Less antiretroviral-associated increase in total 
cholesterol in patients with 322G/G.
Mallal et al. [25] HLA-B HLA-B*5701 185 87% Australasia 89% White Association between HLA-B*5701 and 
hypersensitivity to abacavir.
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predominantly non-Hispanic/White 
men, and studied polymorphisms that 
occur infrequently within populations. 
As a result, conﬂ  icting associations have 
been found [16,26–29], and the clinical 
applicability of results is unclear.
    Notable exceptions include a 
study showing a high incidence of 
hypersensitivity to the nucleoside 
reverse transcriptase inhibitor abacavir 
in patients with the HLA-B*5701 
halotype [25], and another study 
that demonstrated signiﬁ  cant racial/
ethnic differences in the frequency of 
polymorphisms in the gene-encoding 
cytochrome P450 2B6, which is 
responsible for metabolism of the 
non-nucleoside reverse transcriptase 
inhibitor efavirenz. The differences in 
the frequency of these polymorphisms 
help explain the observed differences 
in metabolism of this drug between 
different racial/ethnic groups [22]. 
The latter study was also performed as 
part of the AACTG collaboration.
  Future  Directions
    Of the 43 million people estimated 
to be currently living with HIV, 43% 
are women, 64% live in sub-Saharan 
Africa, 18% live in South and Southeast 
Asia, and 4.5% live in Latin America 
[18]. Although we still have much to 
learn about the importance of race and 
ethnicity in the long-term treatment of 
HIV, studies such as that by Foulkes et 
al. underscore the importance of both 
race/ethnicity and genetic factors in 
the long-term treatment of HIV.
    The study by Foulkes et al. 
underscores the importance of 
designing appropriately powered 
pharmacogenetic studies that include 
individuals from a wide variety of 
racial/ethnic backgrounds in order 
to determine the clinical importance 
of genetic variation. Although DNA 
banks raise ethical challenges [30], 
collaborations such as the AACTG 
are an ideal framework in which to 
perform these studies. Establishing 
and supporting similar collaborative 
groups in other regions of the world 
is essential if further useful studies are 
to be performed in this ﬁ  eld. Such 
studies are vital if the eventual goal of 
safe long-term therapy for HIV is to be 
realised worldwide.   
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